A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality.
Journal
Experimental and clinical psychopharmacology
ISSN: 1936-2293
Titre abrégé: Exp Clin Psychopharmacol
Pays: United States
ID NLM: 9419066
Informations de publication
Date de publication:
05 Oct 2023
05 Oct 2023
Historique:
medline:
5
10
2023
pubmed:
5
10
2023
entrez:
5
10
2023
Statut:
aheadofprint
Résumé
The present study sought to determine the effects of cannabinol (CBN) alone and in combination with cannabidiol (CBD) on sleep quality. This was a double-blind, randomized, placebo-controlled study conducted between May and November 2022. Participants were randomized to receive either (a) placebo, (b) 20 mg CBN, (c) 20 mg CBN + 10 mg CBD, (d) 20 mg CBN + 20 mg CBD, or (e) 20 mg CBN + 100 mg CBD for seven consecutive nights. Participants were 18-55 years of age who self-rated sleep quality as "very poor" or "poor." The primary endpoint was sleep quality, while secondary endpoints included sleep onset latency, number of awakenings, wake after sleep onset (WASO), overall sleep disturbance, and daytime fatigue. In a modified intent-to-treat analyses (
Identifiants
pubmed: 37796540
pii: 2024-14146-001
doi: 10.1037/pha0000682
doi:
Banques de données
ClinicalTrials.gov
['NCT05839964']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Canopy Growth Corporation